

**Anti-IL-6Ra / CD126 Reference Antibody (tocilizumab)
Recombinant Antibody
Catalog # APR10735****Specification**

Anti-IL-6Ra / CD126 Reference Antibody (tocilizumab) - Product Information

Application	FC, E, FTA
Primary Accession	P08887
Reactivity	Cynomolgus, Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145.2 KDa

Anti-IL-6Ra / CD126 Reference Antibody (tocilizumab) - Additional Information**Target/Specificity**
IL-6Ra / CD126**Endotoxin**
< 0.001EU/ µg,determined by LAL method.**Conjugation**
Unconjugated**Expression system**
CHO Cell**Format**
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Storage**
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.**Anti-IL-6Ra / CD126 Reference Antibody (tocilizumab) - Protein Information****Name** IL6R ([HGNC:6019](#))**Function**
Part of the receptor for interleukin 6. Binds to IL6 with low affinity, but does not transduce a signal (PubMed:28265003). Signal activation necessitate an association with IL6ST. Activation leads to the regulation of the immune response, acute-phase reactions and hematopoiesis (PubMed:30995492, PubMed:31235509). The interaction with membrane-bound IL6R and IL6ST stimulates 'classic signaling', the restricted expression of the IL6R limits classic IL6 signaling to only a few tissues such as the liver and some

cells of the immune system. Whereas the binding of IL6 and soluble IL6R to IL6ST stimulates 'trans- signaling'. Alternatively, 'cluster signaling' occurs when membrane- bound IL6:IL6R complexes on transmitter cells activate IL6ST receptors on neighboring receiver cells (Probable).

Cellular Location

[Isoform 1]: Cell membrane {ECO:0000250|UniProtKB:P22272}; Single-pass type I membrane protein [Soluble interleukin-6 receptor subunit alpha]: Secreted

Tissue Location


[Isoform 2]: Expressed in peripheral blood mononuclear cells and weakly found in urine and serum. 1%-20% of the total sIL6R in plasma is generated by alternative splicing (PubMed:28060820).

Anti-IL-6Ra / CD126 Reference Antibody (tocilizumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-IL-6Ra / CD126 Reference Antibody (tocilizumab) - Images




Anti-IL-6Ra / CD126 Reference Antibody (tocilizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%




The purity of Anti-IL-6Ra / CD126 Reference Antibody (tocilizumab) is more than 95% ,determined

by SEC-HPLC.



Human IL-6R CHO cells were stained with Anti-IL-6Ra / CD126 Reference Antibody (tocilizumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC801=0.4525 nM



Anti-IL-6Ra / CD126 Reference Antibody (tocilizumab)-induced FACS Blocking activity was evaluated using Human IL-6R CHO cells. The IC50 was approximately 1.303nM.